Can Eli Lilly get its R&D act together?

Eli Lilly's recent late-stage pratfall in Alzheimer's set the stage for a blistering Fortune piece dissecting the yawning gap between the Big Pharma's R&D game plan and its woeful track record. Just as some of its biggest competitors are absorbing pipelines stuffed with potential new products, Lilly has avoided any big merger deals. And analysts question whether CEO John Lechleiter (photo) has pointed the company down a blind alley. Its one big R&D success of the past five years,...